Finding effective treatments and ultimately


Our Impact to Date


Direct Investment in Fragile X Research

What is Fragile X Syndrome?

Fragile X syndrome (FXS) is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4,000 boys and 1 in 6,000 girls worldwide.

Fragile X syndrome occurs when a single gene on the X chromosome shuts down. This gene makes a protein needed for normal brain development. In FXS it does not work properly, the protein is not made, and the brain does not develop as it should.

Learn more about Fragile X syndrome

How Does FRAXA Help?

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.

Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.

Donate to FRAXA's mission

Upcoming Events

No event found!

Latest Fragile X News & Updates

Boston Bruins Foundation to Hold 50/50 Jackpot Raffle to Benefit FRAXA

The Boston Bruins of the National Hockey League (NHL) are once again supporting Fragile X research! The team’s charity, the Boston Bruins Foundation, is having a special jackpot giveaway to support FRAXA Research Foundation. And this year they are selling raffle tickets online! The Boston Bruins Foundation’s 50/50 raffle is now live with half the proceeds going to a lucky winner and the other half going to help find effective treatments and ultimately a cure for Fragile X.
Read more

Metformin and Aberrant Insulin Signaling in a Fragile X Mouse Model

This 2017-2018 grant of $90,000 is funded jointly by FRAXA and the Fragile X Research Foundation of Canada for the first year. A previous FRAXA grant to the Sonenberg lab has led to great interest in the available drug, metformin, as a potential treatment for Fragile X syndrome. FRAXA is currently organizing clinical trials of metformin.
Read more

Research Points to Drugs which Inhibit PDE to Treat Fragile X

FRAXA Research Foundation funded a grant of $90,000 over 2016-2018, for a postdoctoral fellowship for Thomas Maurin, PhD, working under the mentorship of Dr. Barbara Bardoni at INSERM in France. The team works on the biochemistry of the Fragile X protein. They have found that PDE inhibitors (a class of drugs) show promise as treatments for Fragile X syndrome. In related research, FRAXA is currently funding a clinical trial of PDE4D inhibitors.
Read more

Current Fragile X Research

Funded by FRAXA Research Foundation


Teams actively researching Fragile X

Current Research Grants
FRAXA X - transparentFRAXA X - transparent


Pharmaceutical and Biomedical Partners

FRAXA X - transparentFRAXA X - transparent


ongoing fragile x clinical trials and studies

Current Clinical Trials & Studies
FRAXA X - transparentFRAXA X - transparent


Countries are home to research teams

FRAXA X - transparentFRAXA X - transparent


gene therapy and protein replacement studies

Current Studies
FRAXA X - transparentFRAXA X - transparent